OTR Therapeutics Raises $100 Million in Series A Financing to Advance Early Innovation into Global Transformative Therapies

▤ Summary

OTR Therapeutics has emerged from stealth with a $100 million Series A financing round backed by major investors including True Light Capital, LAV, Pfizer Ventures, and Sirona Capital. The company is building a capital-efficient biotech model that combines internal R&D with selective external asset acquisition. It plans to use the new capital to advance its pipeline in immunology, inflammation, oncology, cardiometabolic disease, and other high-unmet-need areas. OTR also acquired a preclinical neurological program as part of its strategy to expand its development pipeline and accelerate global clinical translation.

$ Funding

▦ Linked Companies